Trial Profile
Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Bevacizumab; Irinotecan
- Indications Glioblastoma
- Focus Therapeutic Use
- 23 Aug 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 02 Oct 2009 New trial record